Just a follow up from my last post re Zenith liquidity...a couple of thoughts/opinions/feelings I want to get off my mind.

I have held RVX shares for about 8 years and one of the things that struck me is that RVX has a strong science focus (almost like an academic institution) and less of a business focus. Fund raising has been successful in large part due to the billionaires (Ken Dart and Hepalink) as well as NGN Capital. These companies have have applied their resources in scientific knowledge to do their DD. They know the inside information and have direct access to the science and management people at RVX. They also serve a role in connecting RVX to world wide expertise and resources. This underscores the belief in the scientific path that RVX is on.

I've put my faith behind that thinking yet as we all know the billionaires have many millions of $ to put out to numerous biotech, tech companies, social media startups, etc and if they "hit" on one success they've paid back the rest of the bets and will make hundreds of millions. So my reasoning may be flawed.

However, rvx-208 has many years of successes and the good news continues to flow as they pursue the science further and discover more info about the cascading epigenetic mechanisms of rvx-208. Zenith, from what I understand, has a treasure trove of epigenetic platforms that have evolved for many years recently as well as when Zenith was part of RVX. So there is a huge store of scientific knowledge bottled up within these organizations and most of us feel the current share price is very significantly below a drug in phase lll trials.

My interest is further enhanced by what I believe was a new direction taken by Resverlogix about 10 years ago when Dr Wong tuned in to a scientific paper or something said by either Crick or Watson (of Double Helix fame - the discovers of the structure of DNA). As everyone knows these scientists are (were - one of them has passed away) Nobel Laureates. Anyway, one of them said something to the effect that "epigenetics" (the software that runs the genetic machinery) will be the next big area in biological and medical discovery. As I understand, Dr Wong paid serious attention to this and shifted the RVX research. Sort of funny when we think about the tech industries where developers are making hundreds of millions on developing "apps". Epigenetic development is a bit like "app" development but applied to genetic structures.

Don M continues to claim that RVX has an 8 year lead on any other competitor regarding epigenetic drug development. We've seen the results with the tremendous success of rvx-208 in terms of ApoA-l production, inflammation, reverse cholesterol transport, etc (refer to their websites, releases and publications). They are invited to present at prestigious scientific and business conferences.

I apologize to readers because of my "rough recall" of the developments but I don't have the time to keep a detailed list. It is all available and much of it is in BDAZ posts.

So I am extremely excited because of the science.

However, the reason I wrote this stream of consciousness post is to clear my mind and state my guess about the next few years (and I dearly want to be proven wrong!!! - not that the direction is bad...it just has little monetary benefit in the near term). So my guess, and it purely a guess, is that the next 3 years will essentially continue with a strong scientific focus with little opportunity for investors to benefit. Some traders will benefit but longs like me are just going to have to wait for BETonMACE success. Now there could be some near term value drivers as we have all speculated.

1. As each month or two progresses on the BETonMACE trial more investors will be watching. Dosing has started.
2. Successes in orphan trial results could generate a revenue stream while BOMonMACE continues.
3. Success of an orphan trial will raise the profile with BP and investors and science.
4. There may be new regional deals and Don has hinted at some regions.
5. Further discoveries of the impact of rvx-208 will fuel interest.
6. Scientific publications re epigenetics will drive the interest in the field of epigenetics.
7. I do believe that a NASDAQ listing would bring significant credibility and market reach that would drive the share price. Coming in to this stock even at $10 or $20 in the next year is still a very reasonable price to pay for the potential of huge returns if BoM is successful. Dart, Hepa and NGN are not there for chump change.
8. Analysts coverage is improving and there may be a trigger point for higher profile coverage before the end of BoM.

So I wrote this rambling because of the lack of liquidity of Zenith shares. It has been 2 and 2/3rds years since Zenith was created. I am not seeing any evidence of the liquidity issue being resolved. My guess is that they have allot of learning to do before they go to NASDAQ. The only thing I can think of is the need for funding for trails and administrative expenses.

I would truly love to see liquidity addressed for Zenith fast but I do not see any hope in the near term (next year).

Anyway, Don, please prove me wrong.

Toinv